Sugi Predict

Sugi Predict / Compounds / SCHEMBL400917

SCHEMBL400917

SCHEMBL400917

Nc1ncnc2c1c(-c1cc3nc(Oc4ccccc4)ccc3cc1Cl)nn2C1=CC=C1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 6/20 0.39
▸ BTK Q06187 9/20 0.39
▸ PIK3CD O00329 4/20 0.39
▸ PIK3CA P42336 4/20 0.39
▸ PIK3CB P42338 4/20 0.39
▸ PIK3CG P48736 4/20 0.39
▸ PRKDC P78527 4/20 0.39
▸ EGFR P00533 3/20 0.39
▸ ABL1 P00519 3/20 0.39
▸ HCK P08631 2/20 0.39
▸ KDR P35968 2/20 0.39
▸ MTOR P42345 2/20 0.39
▸ EPHB4 P54760 2/20 0.39
▸ NUDT14 O95848 1/20 0.39
▸ NUDT5 Q9UKK9 1/20 0.39
▸ MAP4K4 O95819 2/20 0.39
▸ BLK P51451 1/20 0.37
▸ LCK P06239 1/20 0.35
▸ LYN P07948 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL400802 0.86 NUDT14 (0.48) SRCBTKPIK3CDPIK3CAPIK3CB
SCHEMBL396338 0.85 SRC (0.44) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL400243 0.83 SRC (0.40) SRCBTKEGFRABL1KDR
SCHEMBL400392 0.82 SRC (0.39) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL400916 0.80 BTK (0.58) SRCBTKPIK3CDPIK3CAPIK3CB
SCHEMBL397797 0.79 BTK (0.49) SRCBTKPIK3CDPIK3CAPIK3CB
SCHEMBL401212 0.79 SRC (0.36) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL398651 0.77 BTK (0.49) SRCBTKPIK3CDPIK3CAPIK3CB
Carbamic Acid SCHEMBL19244736 0.77 BTK (0.55) SRCBTKPIK3CDPIK3CAPIK3CB
SCHEMBL397876 0.76 BTK (0.51) SRCBTKEGFRABL1HCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735405-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-05-27 — — US claimed
US-20120196847-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2012-08-02 — — US claimed
EP-2168968-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2010-03-31 — — EP claimed
US-20080299113-A1 Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents OSI PHARMACEUTICALS, INC. 2008-12-04 — — US claimed
EP-1979002-A2 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI Pharmaceuticals, Inc. (US) 2008-10-15 — — EP claimed
WO-2008076143-A1 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI PHARMACEUTICALS, INC. (US) 2008-06-26 — — WO claimed
US-20080014200-A1 Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents OSI PHARMACEUTICALS, INC. 2008-01-17 — — US claimed
WO-2007075554-A2 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI PHARMACEUTICALS, INC. (US) 2007-07-05 — — WO claimed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US claimed
EP-2168968-B1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS LLC (US) 2017-08-23 — — EP disclosed
US-8735405-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-05-27 — — US disclosed
US-8653268-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-02-18 — — US disclosed
US-8575164-B2 Combination cancer therapy OSI Pharmaceuticals, LLC (US) 2013-11-05 — — US disclosed
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2013-07-25 — — US disclosed
US-20080267957-A1 Combination cancer therapy OSI PHARMACEUTICALS, INC. 2008-10-30 — — US disclosed
EP-1979002-A2 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI Pharmaceuticals, Inc. (US) 2008-10-15 — — EP disclosed
WO-2008076143-A1 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI PHARMACEUTICALS, INC. (US) 2008-06-26 — — WO disclosed
US-20080014200-A1 Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents OSI PHARMACEUTICALS, INC. 2008-01-17 — — US disclosed
WO-2007075554-A2 COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT OSI PHARMACEUTICALS, INC. (US) 2007-07-05 — — WO disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885BTK 146/4885PIK3CD 448/4885
US-20080014200-A1 Combined treatment with 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents IGF1R, IGFBP6, CDK6 SRC 292/4885BTK 301/4885PIK3CD 312/4885
US-20080299113-A1 Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents IGF1R, EGFR, ERBB2 SRC 35/4885BTK 77/4885PIK3CD 157/4885
US-20120196847-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885BTK 146/4885PIK3CD 448/4885
US-20080267957-A1 Combination cancer therapy IGF1R, IGFBP4, IGFBP1 SRC 358/4885BTK 506/4885PIK3CD 800/4885
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors IGF1R, MAP2K7, BRCA1 SRC 299/4885BTK 146/4885PIK3CD 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.